Healthark Insights

Look Back at the Top Healthtech #Trends of 2024 From groundbreaking advancements in #AI and robotics to the continued growth of mental health innovations, the #healthtech industry saw remarkable progress last year! What’s next for #healthcare? Get ready as we prepare to unveil the Top Healthtech Trends of 2025! #HealthtechTrends #HealthcareInnovation #AIInHealthcare #Telehealth #PrecisionMedicine #TopTrends #FutureOfHealth #2025Trends

The Business of Innovation: #Oncology M&A and Partnerships in 2024 The #pharmaceutical industry is buzzing with activity, with 57 major deals in oncology alone between Q4 2023 and Q3 2024. These collaborations are reshaping the landscape of #cancer treatment by bringing innovative solutions to market faster. The future of oncology lies in #collaboration. Let’s keep pushing the boundaries of innovation! Swipe through to explore how #acquisitions and collaborations are driving the #future of oncology! #OncologyInnovation #HealthcareTransformation #PharmaDeals #CancerCare #PartnershipsInHealthcare

Global spending on #oncology reached $255 billion in 2024! As #cancer care evolves with cutting-edge treatments and increased access to therapies, what do you believe is the key driver of this significant cost increase? Vote below! Refer to our full #report for more insights: https://lnkd.in/eDykJNMq #Oncology #GlobalSpending #NovelTherapies #Biologics #PrecisionMedicine

Transforming Cancer Care: Key #Trends and Insights in Oncology The oncology landscape is advancing rapidly, driven by remarkable progress in sales and therapeutic innovation. What’s fueling this #growth? Biosimilars and Generics: FDA approvals of 2 generic medications and 6 biosimilars in H1 2024. Innovative Therapies: Novel treatments like CAR-T, ADCs, and multi-specific antibodies, which now account for 85% of launches, are significantly increasing treatment costs. Top Performing Oncology #Drugs: Keytruda leads the way with $27B in sales (+37.7%). Strong growth from Darzalex (+38%) and Imfinzi (+47.7%). Spending on PD-1/PD-L1 inhibitors is projected to reach $54.8B, highlighting their importance in treating solid tumors. Global Markets Driving #Progress: Major regions like the US, EU, and China are leading the charge, accelerating innovation and transforming cancer care worldwide. The #future of oncology is brighter than ever, bringing hope and cutting-edge solutions to patients. Dive deeper into these trends: https://lnkd.in/eDykJNMq #Oncology #HealthcareInnovation #CancerResearch #PrecisionMedicine

2024 was a groundbreaking year for oncology #FDA approvals, with over 50 new or expanded indications, including 18 new oncology agents and 9 T cell-engaging bispecific antibodies. The #approvals highlighted a strong focus on solid tumours (23 approvals) and haematological malignancies (9 approvals), alongside the inclusion of 31 biologics and 6 #biosimilars. These milestones underscore the rapid pace of #innovation and the unwavering commitment to addressing unmet needs in cancer care. Explore the full list and detailed #insights in our report: https://lnkd.in/eDykJNMq #OncologyInnovation #FDAApprovals #CancerCare #DrugDevelopment

The #oncology sector is seeing a surge in M&A and collaborations! In 2024, 14 oncology-related #pharma deals are making waves, with Merck & Daiichi-Sankyo leading the charge with a $10.1B #collaboration. Key trends include a focus on antibody-drug conjugates (#ADCs), AI-driven #drug discovery, and big pharma acquisitions targeting cutting-edge therapies. These #developments are shaping the future of cancer treatment and accelerating progress for patients worldwide. #MergersAndAcquisitions #Innovation #PharmaTrends #CancerResearch

We are thrilled to announce the release of our latest Oncology Report, highlighting the transformative progress being made in the fight against advanced #cancers. Here's a glimpse of what’s inside: #PrecisionMedicine: Focused on underserved patient subpopulations #InnovativeTherapies: Antibody-drug conjugates and radioligand therapies are taking center stage in clinical trials. Improved Success Rates: #Oncology clinical development success rates reached 12% in 2024, up from 10% in 2023, driven by streamlined trials and enhanced productivity. #AIinResearch: Artificial intelligence is shaping the future of oncology, boosting efficiency and driving breakthroughs. Comprehensive Insights: From top medications and spending trends to #regulatory updates and M&As, this report offers a global perspective. The relentless pursuit of better outcomes for cancer patients continues to be fueled by scientific innovation and collaborative efforts. Discover the details: https://lnkd.in/eDykJNMq Together, let’s accelerate progress in oncology and improve lives around the world. #Oncology #PrecisionMedicine #Innovation #Healthcare

Discover how Regex, TF-IDF, and BERT combine to revolutionize keyword extraction. From enhancing #clinical decision support to automating #healthcare report classification, this approach delivers precision, context, and deep understanding. Dive into the blog to explore how these techniques are driving smarter, faster #decision-making across industries: https://lnkd.in/dWkgawvu #KeywordExtraction #NLP #MachineLearning #Regex #TFIDF #BERT #DataScience #HealthcareAI #ArtificialIntelligence

Meet Thakur Pratap Hansda, a valued Senior Consultant at Healthark Insights, who has been an integral part of our team for the past 3 years. His passion for crafting impactful #healthcare solutions and unwavering commitment to excellence have made a lasting impact on our projects and teams. We are grateful for his dedication and the valuable contributions he continues to make. #HealthcareConsulting #Teamwork #EmployeeTestimonial #CareerGrowth

We partnered with a leader in precision #oncology to advance cancer care through cutting-edge machine learning (#ML) solutions. By leveraging advanced genomic data, we tackled the critical challenge of predicting novel genetic variants and identifying cancer-driving genes. Here’s how we made an impact: ·        Data Cleaning: Streamlined #genetic data to focus on meaningful variations, ensuring accuracy and reliability ·        Feature Engineering & Clustering: Designed a robust feature set and segmented data by chromosomes for #targeted analysis ·        Modelling & Variants Prediction: Deployed ensemble ML models (Random Forest, XGBoost, Extra Trees) to predict pathogenic variants with 98% #accuracy ·        Sample-wise Clustering: Applied #clustering to uncover meaningful genetic patterns and potential therapeutic targets The Outcome? Identified novel driver genes with pathogenic variants, providing actionable insights for #personalised cancer therapies and redefining precision oncology practices. Explore how Healthark Insights is driving #innovation in healthcare through data-driven solutions. Read the full case study on our website: https://lnkd.in/daz4yrJu #PrecisionOncology #Genomics #MachineLearning #CancerCare #DataScience #HealthcareInnovation #PathogenicVariants #TargetedTherapies